Patent US5200176A successfully refreshed from Google Patents.
US5200176A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for protection of ischemic tissues using tumor nerosis factor
Assignee: Genentech Inc
•
Filing: 1989-10-06
•
Granted: 1993-04-06
•
Expires: 2009-10-06
Abstract
Abstract Methods suitable for the protection, inhibition and prevention the deleterious effects of reactive oxygen species are provided, wherein an effective amount of a tumor necrosis factor is administered. Pretreatment of tissues and organs to be transplanted is described. Perfusion solutions and the preparation of perfused, excised tissue are described.
Inventors
- 👤 Grace H. W. Wong
- 👤 David V. Goeddel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 15:49
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/191; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/144
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
26 words
A method for the protection of ischemic tissues, comprising the administration to said tissue prior to reperfusion of an effective amount of a tumor necrosis factor.
Claim 2
Independent Claim
26 words
A method for the protection of ischemic tissues, comprising the administration to said tissue prior to reperfusion of an effective amount of a tumor necrosis factor.
Claim 3
Dependent Claim
23 words
The method of claim 1, wherein said tumor necrosis factor is administered prior to or after removal of said tissue from a donor.
Claim 4
Dependent Claim
23 words
The method of claim 1, wherein said tumor necrosis factor is administered prior to or after transfer of said tissue to a patient.
Claim 5
Dependent Claim
25 words
The method of claim 1, wherein said tissue has been or is to be removed from a mammalian donor and transferred into a mammalian patient.
Claim 6
Dependent Claim
10 words
The method of claim 1, wherein said tissue is mammalian.
Claim 7
Dependent Claim
18 words
The method of claim 1, wherein said tumor necrosis factor is administered along with alpha, beta, or gamma-interferon.
Claim 8
Dependent Claim
17 words
The method of claim 1, wherein approximately 1-250 μg/m 2 of said tumor necrosis factor is administered.
Claim 9
Dependent Claim
18 words
The method of claim 1, wherein said tumor necrosis factor is tumor necrosis factor-α or tumor necrosis factor-β.
Claim 10
Dependent Claim
18 words
The method of claim 1, wherein said tumor necrosis factor is perfused into said tissue by mechanical means.
Claim 11
Dependent Claim
21 words
The method of claim 1, wherein said tumor necrosis factor is continuously perfused through said tissue with a pharmaceutically acceptable excipient.
Claim 12
Dependent Claim
65 words
The method of claim 10, wherein said tumor necrosis factor is perfused into said tissue before or after the tissue has been removed from a donor but prior to the implantation of said tissue into a patient, and wherein said tumor necrosis factor is replaced by an isotonic perfusion fluid free of tumor necrosis factor immediately prior to implantation of the tissue into said patient.
Claim 13
Dependent Claim
19 words
The method of claim 1, wherein said tumor necrosis factor is administered along with an antioxidant or fibrinolytic agent.
Claim 14
Independent Claim
41 words
A method for the protection of ischemic tissue to be removed from a donor and transferred to a patient, comprising the administration to said donor prior to the removal of said tissue of an effective amount of a tumor necrosis factor.
Claim 15
Independent Claim
41 words
A method for the protection of ischemic tissue to be removed from a donor and transferred to a patient, comprising the administration to said donor prior to the removal of said tissue of an effective amount of a tumor necrosis factor.
Claim 16
Dependent Claim
13 words
The method of claim 13, wherein said donor and said patient are mammalian.
Claim 17
Dependent Claim
18 words
The method of claim 13, wherein said tumor necrosis factor is administered along with alpha, beta, or gamma-interferon.
Claim 18
Dependent Claim
17 words
The method of claim 13, wherein approximately 1-250 μg/m 2 of said tumor necrosis factor is administered.
Claim 19
Dependent Claim
18 words
The method of claim 13, wherein said tumor necrosis factor is tumor necrosis factor-α or tumor necrosis factor-β.
Claim 20
Dependent Claim
16 words
The method of claim 13, wherein said tumor necrosis factor is administered to said donor intravenously.
Claim 21
Dependent Claim
19 words
The method of claim 13, wherein said tumor necrosis factor is administered along with an antioxidant or fibrinolytic agent.
Claim 22
Dependent Claim
42 words
The method of claim 1, wherein said tissue is selected from the group consisting of muscle tissue, connective tissue, epithelial tissue, nervous tissue, vascular tissue, brain, reproductive organs, respiratory organs, digestive organs, excretory organs, urinary organs, sensory organs, and skeletal muscle organs.
Claim 23
Dependent Claim
42 words
The method of claim 13, wherein said tissue is selected from the group consisting of muscle tissue, connective tissue, epithelial tissue, nervous tissue, vascular tissue, brain, reproductive organs, respiratory organs, digestive organs, excretory organs, urinary organs, sensory organs, and skeletal muscle organs.
References Cited (Backward Citations)
EP0164965A2
Cited
EP0168214A2
Cited
EP0235906A1
Cited
EP0239289A1
Cited
US4846782A
Cited
US4861587A
Cited
EP0259863A2
Cited
US4985241A
Cited
EP0284105A2
Cited
US4808402A
Cited
EP0340005A2
Cited
EP0357240A2
Cited
WO1991015227A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-05 | 1996-10-05 | 1997-04-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-05 | 2000-10-05 | 2001-04-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-05 | 2004-10-05 | 2005-04-06 | $7700.00 | Window Closed / Lapsed |